← All trials
NCT04312048
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 25, 2020
- Primary completion
- Jun 25, 2020
- Completion date
- Jul 1, 2020
- First posted
- Mar 18, 2020
- Last posted
- Mar 18, 2020
- Enrollment
- 84
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Cairo UniversityLead sponsor
- Cairo UniversityOverall official - principal investigator
- Cairo UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.